MBX Biosciences, Inc. Common Stock (MBX)
Intrinsic Value
Negative or zero free cash flow — company is in reinvestment/growth phase.
Alternative Approach:
Use EV/Sales or revenue multiples for high-growth companies.
DCF-based fair value calculation with Bear, Base, and Bull scenarios
Negative or zero free cash flow — company is in reinvestment/growth phase.
Alternative Approach:
Use EV/Sales or revenue multiples for high-growth companies.
Insufficient data to compute DCF valuation for MBX. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For MBX, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.